Related Experiment Video
Updated: Jan 30, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Crizotinib-induced lichenoid drug eruption in a patient with lung cancer
1Department of Dermatology, National Yang-Ming University, Taipei, Taiwan.
Abstract:
Crizotinib was approved by the US Food and Drug Administration in 2011 for the treatment of anaplastic lymphoma kinase (ALK)- or ROS1-positive non-small cell lung cancer (NSCLC). Since then, the number of indicated uses for crizotinib has substantially increased. However, the administration of crizotinib can be associated with various adverse events. It is important that clinicians identify adverse cutaneous manifestations of crizotinib and are aware of their outcomes and treatments to avoid unnecessarily discontinuing a potentially life-saving medication. We describe a case of lichenoid drug eruption (LDE) that appeared 4 weeks after initiation of treatment with crizotinib in a 61-year-old man with ALK-positive metastatic lung adenocarcinoma.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Related Concept Videos
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Mechanisms of Retrovirus-induced Cancers